FDA posted a CDER warning letter for Sato Pharmaceutical Co., Ltd. after inspecting the firm's Hachioji, Tokyo facility in November 2025. The letter covers CGMP issues for finished drug products, including sterile manufacturing controls and stability testing for OTC products in the U.S. market.
The useful signal is specific. FDA did not point to one isolated deviation. The agency described a filling line where the design, airflow evidence, and contamination history did not support confidence in aseptic control.
Media fills made the risk visible
FDA wrote that Sato had at least six media-fill failures between November 2022 and February 2025. Media fills test whether an aseptic process can run without microbial contamination. Repeated failures tell quality teams to treat the line as a system problem, not a paperwork problem.
The letter also described microbiological and foreign particulate contamination on the line. That matters because sterile-drug operations depend on layered controls. Operators, equipment, airflow, environmental monitoring, interventions, cleaning, and validation all have to support the same conclusion: exposed sterile product stays protected.
Airflow evidence did not carry the claim
FDA also criticized the ISO 5 area and restricted access barrier system. The agency said first-pass air did not reach the filling line, leaving critical ISO 5 zones unprotected while sterile drug products were exposed.
The warning letter pushed beyond the airflow conclusion and questioned the evidence behind it. FDA cited airflow visualization studies where the smoke source moved too quickly, the smoke source position limited full-height evaluation, and a technician blocked visibility.
That is a useful compliance lesson. An airflow study does not help much if the study cannot show what happens where product is exposed. A clean-room team needs video evidence that matches the critical operation, not only a protocol that says the study happened.
Stability testing added a second control gap
The Sato letter also cited inadequate laboratory testing and an inadequate stability program. FDA said the firm lacked stability-indicating methods for OTC products in the U.S. market and did not monitor or evaluate impurity peaks in some HPLC analyses.
FDA also pointed to stability protocols that omitted critical quality attributes. For a finished-drug manufacturer, that creates a shelf-life problem. The firm has to show that products continue to meet specifications over time, including degradation, content, dose uniformity, particulate matter, and other attributes tied to product quality.
Checks teams can run from this signal
Sterile-drug and OTC quality teams can turn the public letter into a short internal check:
- Do media-fill investigations treat repeat failures as a line-control issue?
- Do smoke studies show the actual exposed-product zones with clear visibility?
- Does the RABS or ISO 5 design deliver first-pass air where the process needs it?
- Do stability methods identify degradation and impurity changes over shelf life?
- Do stability protocols include the quality attributes customers and FDA would expect to see?
The Sato letter is worth watching because it connects manufacturing design, validation evidence, contamination history, and stability data in one public FDA record.
Source
FDA warning letter, Sato Pharmaceutical Co., Ltd., posted May 2026